Black Diamond Therapeutics Inc banner

Black Diamond Therapeutics Inc
NASDAQ:BDTX

Watchlist Manager
Black Diamond Therapeutics Inc Logo
Black Diamond Therapeutics Inc
NASDAQ:BDTX
Watchlist
Price: 2.58 USD 3.2% Market Closed
Market Cap: $147m

Multiples-Based Value

The Multiples-Based Value for Black Diamond Therapeutics Inc (BDTX) under the Base Case is hidden USD. Compared with the current market price of 2.58 USD, the stock appears hidden .

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BDTX Multiples-Based Value
LOCKED
Unlock
Worst Case
Base Case
Best Case

Multiples Across Competitors

BDTX Competitors Multiples
Black Diamond Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Black Diamond Therapeutics Inc
NASDAQ:BDTX
147.4m USD 2.1 6.6 1 1
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
375.5B USD 6.1 89.7 14.8 20.6
US
Amgen Inc
NASDAQ:AMGN
188.5B USD 5.2 24.8 14.4 14.4
US
Gilead Sciences Inc
NASDAQ:GILD
175.7B USD 6 20.7 12.9 16
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.8B USD 9.5 28.7 21.6 22.5
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82B USD 5.7 18 13.5 15.4
NL
argenx SE
XBRU:ARGX
41.9B EUR 11.8 37.9 40.9 41.8
AU
CSL Ltd
ASX:CSL
68.5B AUD 3 33.1 11.1 14
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
P/S Multiple
Revenue Growth P/S to Growth
US
Black Diamond Therapeutics Inc
NASDAQ:BDTX
Average P/S: 3 063 003
2.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.1
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.2
3%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
6
5%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.5
11%
0.9
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
10%
0.6
NL
argenx SE
XBRU:ARGX
11.8
28%
0.4
AU
CSL Ltd
ASX:CSL
3
4%
0.7
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
P/E Multiple
Earnings Growth PEG
US
Black Diamond Therapeutics Inc
NASDAQ:BDTX
Average P/E: 32.4
6.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
89.7
97%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.8
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
20.7
16%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.7
17%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
13%
1.4
NL
argenx SE
XBRU:ARGX
37.9
32%
1.2
AU
CSL Ltd
ASX:CSL
33.1
10%
3.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Black Diamond Therapeutics Inc
NASDAQ:BDTX
Average EV/EBITDA: 16.3
1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.8
12%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.4
10%
1.4
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
9%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.6
16%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.5
18%
0.7
NL
argenx SE
XBRU:ARGX
40.9
50%
0.8
AU
CSL Ltd
ASX:CSL
11.1
7%
1.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Black Diamond Therapeutics Inc
NASDAQ:BDTX
Average EV/EBIT: 18.2
1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
20.6
23%
0.9
US
Amgen Inc
NASDAQ:AMGN
14.4
3%
4.8
US
Gilead Sciences Inc
NASDAQ:GILD
16
13%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.5
17%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.4
23%
0.7
NL
argenx SE
XBRU:ARGX
41.8
51%
0.8
AU
CSL Ltd
ASX:CSL
14
10%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett